Retatrutide
An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.
What is Retatrutide?
Retatrutide is an investigational triple hormone receptor agonist developed by Eli Lilly, targeting GIP, GLP-1, and glucagon receptors simultaneously. It is not FDA-approved and is currently in Phase III clinical development (the TRIUMPH program). Phase II trials showed up to 24.2% weight loss at 48 weeks, and Phase III TRIUMPH-4 results (December 2025) confirmed 23.7% weight loss at the 12mg dose — an average of 60 pounds lost. Seven Phase III trials are underway, with FDA approval anticipated in late 2026 or 2027.
What Retatrutide Is Investigated For
Retatrutide is investigated primarily for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH), and the strongest evidence to date is for weight loss — Phase 2 trials produced 24.2% mean weight loss at 48 weeks (the largest obesity-drug weight loss ever recorded at that time) and the Phase 3 TRIUMPH-4 readout in December 2025 confirmed 23.7% at 12 mg. A Phase 2a trial in MASH also showed over 80% relative liver-fat reduction and substantial histologic resolution, and a T2D Phase 2 trial reported HbA1c reductions up to 2.02%. The honest caveat is that retatrutide is not yet FDA-approved — most of the Phase 3 SYNCHRONIZE-style TRIUMPH program (including dedicated cardiovascular and NASH outcomes) is still reading out, long-term safety beyond 88 weeks is uncharacterized, and the glucagon component introduces heart-rate and glycemic signals that pure GLP-1 and GIP/GLP-1 agonists do not share. Cross-trial comparisons favoring retatrutide over tirzepatide should be read with that methodological caution in mind.
History & Discovery
Retatrutide (LY3437943) was developed by Eli Lilly as the first triple agonist to reach late-stage obesity trials, simultaneously activating the GIP, GLP-1, and glucagon receptors from a single 39-amino-acid molecule. Its scientific premise built on the preclinical and early clinical success of tirzepatide (dual GIP/GLP-1) and on longstanding interest in glucagon-receptor agonism as a thermogenic and hepatic-fat-mobilizing mechanism — an effect first demonstrated decades ago but difficult to harness therapeutically because of glucagon's hyperglycemic effect. By balancing glucagon-receptor activation against the glucose-lowering effects of GIP and GLP-1, retatrutide's molecular design aims to capture glucagon's energy-expenditure benefit without destabilizing glycemic control. The first-in-patient Phase 1b trial was published in 2022, and the landmark Phase 2 trial in NEJM (2023) reported up to 24.2% weight loss at 48 weeks at the 12 mg dose — the largest obesity-drug weight loss recorded at that time. Lilly's Phase 3 TRIUMPH program began enrolling in 2022 and encompasses at least 7 trials; TRIUMPH-4 headline results reported in December 2025 confirmed 23.7% mean weight loss at the 12 mg dose (average of roughly 60 lb lost). As of early 2026, retatrutide is not FDA-approved; Lilly has signaled anticipated regulatory filing in 2026 with potential approval in late 2026 or 2027.
How It Works
Retatrutide activates three hormone receptors at once: GLP-1 and GIP reduce appetite, while glucagon tells your body to burn more energy and fat. This three-pronged approach produces the most weight loss ever seen in a clinical trial.
Retatrutide is a 39-amino acid peptide with agonist activity at GIPR, GLP-1R, and GCGR. GLP-1R and GIPR activation suppress appetite through hypothalamic and brainstem circuits. GCGR activation increases hepatic fatty acid oxidation, energy expenditure, and thermogenesis. The glucagon component also reduces hepatic steatosis, making it promising for NASH. The three pathways produce complementary and potentially synergistic metabolic effects.
Evidence Snapshot
Human Clinical Evidence
Growing. Phase II showed 24.2% weight loss at 48 weeks. Phase III TRIUMPH-4 confirmed 23.7% at 12mg. Seven Phase III trials underway. Not yet FDA-approved.
Animal / Preclinical
Strong. Triple agonism concept well-supported in preclinical models.
Mechanistic Rationale
Strong. All three receptor pathways are individually well-characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about Retatrutide:
- 01Phase 3 outcomes beyond TRIUMPH-4 — most of the TRIUMPH program (including dedicated cardiovascular, NASH, obstructive sleep apnea, and hypertension outcomes) is still reading out as of early 2026.
- 02Long-term safety beyond 88 weeks — all published and planned trials end at or before that duration; chronic multi-year safety data is not yet available.
- 03Glucagon-specific safety signals — heart rate elevation, modest fasting glucose effects, and possible hepatic effects specific to glucagon-receptor activation require continued characterization at the 12 mg dose over longer exposure windows.
- 04Withdrawal and weight-regain kinetics — no published Phase 3 withdrawal arm data comparable to SURMOUNT-4 or STEP-1 extension; timing and magnitude of regain after discontinuation is inferred rather than measured.
- 05Body composition across the dose range — whether the greater absolute weight loss at 12 mg is accompanied by disproportionate lean mass loss relative to tirzepatide or semaglutide remains under study.
- 06Head-to-head comparison with tirzepatide at maximal dose — no direct trial comparison has been completed, so relative efficacy and tolerability judgments rely on cross-trial indirect comparisons with their inherent limitations.
Forms & Administration
Weekly SC injection. Phase II doses: 1-12mg weekly. Dose titration protocol similar to other incretin drugs. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Retatrutide is investigational; doses below reflect trial protocols, not FDA labeling. The Phase 2 trial (Jastreboff et al., NEJM 2023) evaluated 1, 4, 8, and 12 mg weekly maintenance doses following gradual titration starting at 2 mg. The Phase 3 TRIUMPH program is using maintenance doses of 4, 8, and 12 mg weekly. Titration typically begins at 2 mg weekly and escalates at 4-week intervals (2 → 4 → 8 → 12 mg), analogous to the tirzepatide schedule, to manage GI tolerability.
Frequency
Once weekly by subcutaneous injection in all published and ongoing trials. Trial protocols permit injection on any day of the week, same day each week.
Timing Considerations
Time of day
Once-weekly: same day each week, consistent time of day. The long half-life makes hour-of-day largely irrelevant.
Relative to meals
With or without food.
Relative to exercise
Unrelated to training.
Cycle Length
Retatrutide has not been approved or released for clinical use, so 'protocol length' outside trials is not defined. Phase 2 ran 48 weeks; Phase 3 TRIUMPH trials run 48–88 weeks depending on indication. If retatrutide reaches approval for obesity, the anticipated usage pattern — based on mechanism and on the semaglutide/tirzepatide precedent — will be indefinite chronic use, with substantial weight regain on discontinuation. No withdrawal-specific trial data is yet published.
Protocol Notes
Retatrutide is not legally available outside clinical trials as of early 2026. Trial participants receive investigational drug product through the sponsor. Compounded retatrutide has begun appearing on grey-market and research-chemical websites, but because retatrutide is an unapproved investigational drug, compounding is not authorized and products marketed this way carry unresolved regulatory and product-quality concerns. GI tolerability in Phase 2 was broadly comparable to tirzepatide, with dose-dependent nausea, vomiting, and diarrhea concentrating at titration steps; the glucagon component also raises modest heart-rate elevations (+2–6 bpm) and transient HbA1c excursions at higher doses, which are actively being monitored in Phase 3.
Retatrutide is not FDA-approved and is available only through enrollment in Lilly-sponsored clinical trials. Any non-trial sourcing involves unapproved investigational drug product and is not a medically or legally validated pathway.
Timeline of Effects
Onset
In the Phase 2 trial, weight-loss separation from placebo was visible by week 4 and clearly established by week 12. Appetite suppression is reported within the first 1–2 weeks of dosing, consistent with the GIP/GLP-1 components of the mechanism. HbA1c reductions in type 2 diabetes participants reached statistical separation from placebo by week 8.
Peak Effect
At 48 weeks in the NEJM Phase 2 trial, participants at the 12 mg dose had lost 24.2% of body weight with no clear plateau — the curve was still sloping downward at trial end, suggesting additional weight loss would have accrued with extended exposure. In the type 2 diabetes Phase 2 trial, HbA1c reduction at 36 weeks reached 2.02 percentage points at the 12 mg dose. Peak effect window and plateau point have not been established longitudinally; TRIUMPH Phase 3 with 88-week follow-up will provide those data.
After Discontinuation
No published withdrawal data exist for retatrutide as of early 2026. Based on mechanistic parallels to semaglutide and tirzepatide — both of which show roughly two-thirds weight regain within a year of discontinuation — the working assumption in the field is that retatrutide will behave similarly, with weight regain proportional to the weight lost. The glucagon component's thermogenic effect is also presumed to reverse on discontinuation. These assumptions await trial confirmation.
Monitoring & Measurement
Bloodwork & Labs
- •HbA1c, fasting glucose, fasting insulin (HOMA-IR)
- •Lipid panel — triglycerides especially, because glucagon agonism shifts hepatic lipid handling in a way GLP-1 alone does not
- •ALT and AST — hepatic fat reduction is part of the mechanism; trend matters more than any single value
- •Lipase and amylase at baseline
- •Uric acid — glucagon agonism can nudge this upward in susceptible patients
Functional & Performance Tests
- •Body weight (same scale, weekly)
- •Waist circumference
- •Home blood pressure cuff
- •Resting heart rate (wearable) — this is the most important functional marker for retatrutide
- •DEXA scan if accessible
When to Test
Baseline, 12 weeks, 24 weeks; heart rate tracked weekly at home from the start.
Interpretation & Notes
Phase 2 data showed ~24% body weight loss at 12 mg by week 48 — the largest published result in the class. The glucagon-receptor agonism adds a thermogenic and hepatic-lipid benefit on top of GLP-1/GIP, but also produces a persistent resting heart-rate elevation of roughly 5–8 bpm. That's the tradeoff most worth monitoring: check resting HR at home weekly, and flag a sustained rise above 10 bpm to a clinician before escalating dose. As of 2026 retatrutide is still investigational — not FDA-approved — so source verification, purity testing, and clinical supervision matter more here than with approved analogs. Standard metabolic panels are widely available direct-to-consumer; ALT/AST and uric acid are included in routine comprehensive metabolic panels.
Common Questions
Who Retatrutide Is NOT For
- •Personal or family history of medullary thyroid carcinoma (MTC) — the incretin-class boxed warning is expected to apply to retatrutide based on shared rodent C-cell tumor findings in the class.
- •Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — same mechanistic concern as MTC.
- •Active pancreatitis or history of recurrent pancreatitis — GLP-1 class pancreatitis signal applies; retatrutide trials excluded participants with prior pancreatitis.
- •Pregnancy — investigational drug, no reproductive toxicology data in humans; trial protocols exclude pregnant and breastfeeding participants.
- •Breastfeeding — no data on transfer into milk or infant effects.
- •Severe gastroparesis or significant gastrointestinal motility disorders — delayed gastric emptying from GLP-1 component can worsen symptoms.
- •Pediatric use (under 18) — no pediatric studies; development program is adult-only as of early 2026.
- •Active or decompensated type 1 diabetes — the glucagon component's effect on glycemic control in T1D is inadequately characterized; T1D patients have been excluded from trials.
- •Poorly controlled cardiovascular disease or recent MI — TRIUMPH trials have specific cardiovascular exclusion criteria, and retatrutide's heart-rate effect is larger than tirzepatide's, warranting caution.
Drug & Supplement Interactions
Clinical drug interaction data for retatrutide is limited to trial-protocol observations rather than dedicated pharmacokinetic studies. Based on mechanism, the expected interaction domains parallel tirzepatide: combination with insulin or insulin secretagogues (sulfonylureas, meglitinides) raises hypoglycemia risk and requires downward dose adjustment of those agents; delayed gastric emptying may alter absorption of orally administered drugs, particularly relevant for warfarin (INR monitoring) and levothyroxine (TSH monitoring). The glucagon component introduces a distinct consideration: glucagon-receptor activation can modestly elevate fasting glucose and HbA1c at higher doses, so patients on anti-diabetic therapy need tighter glycemic monitoring than on pure GLP-1 or GIP/GLP-1 agonists. Retatrutide has shown small dose-dependent heart rate elevations (+2–6 bpm on average), which may compound with beta-agonists, thyroid-replacement, stimulants, and sympathomimetics. Because retatrutide is not yet approved, no definitive prescribing-information interaction tables exist; the discussion here is mechanism-inferred and should not be treated as clinically validated guidance.
Safety Profile
Common Side Effects
Cautions
- • Not yet FDA-approved
- • Phase III data still being collected
- • Glucagon component may affect blood sugar differently
- • Long-term safety unknown
What We Don't Know
Phase III cardiovascular outcomes, long-term safety, and optimal dosing are still being determined.
Legal Status
United States
Retatrutide is not FDA-approved for any indication. It is an investigational drug under Eli Lilly's IND, available exclusively through participation in sponsor-run clinical trials (the TRIUMPH program). Pending successful Phase 3 readouts, Lilly has indicated a regulatory filing in 2026, with potential FDA approval in late 2026 or 2027 if the submission is accepted. There is no legal compounding pathway for retatrutide in the US, since compounding under 503A requires either an FDA-approved reference product (which does not exist) or a validated bulk drug substance list entry (which does not apply here). Research-chemical suppliers advertising retatrutide are not operating within an approved clinical or compounding framework.
International
No major regulator — EMA, UK MHRA, Health Canada, Australia's TGA — has authorized retatrutide as a medicine. Lilly's TRIUMPH program has sites in multiple jurisdictions, so trial access varies by country. Personal-use importation of research-chemical retatrutide is prohibited or restricted in most jurisdictions.
Sports & Competition
Retatrutide is not currently listed by name on the WADA Prohibited List, but WADA's S0 category prohibits any substance 'not currently approved by any governmental regulatory health authority for human therapeutic use' — a description that encompasses retatrutide. Athletes subject to WADA code should treat retatrutide as prohibited in and out of competition.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Retatrutide is already available from reputable sources — you just need to know where to look.
Reality
Retatrutide is an unapproved investigational drug. Outside of enrollment in Eli Lilly's TRIUMPH trials, there is no FDA-sanctioned clinical or compounding pathway for obtaining it in the United States. Research-chemical suppliers marketing retatrutide are not operating within any approved framework. Quality, potency, sterility, and exact molecular identity of grey-market product cannot be verified, and acquiring retatrutide from these sources carries real legal and clinical risk beyond the drug itself.
Myth
Retatrutide is just tirzepatide with glucagon added — a minor update.
Reality
Retatrutide is a purpose-designed triple agonist; it is not a combination product or a structural minor variation of tirzepatide. The glucagon-receptor component introduces a distinct mechanism — increased energy expenditure and hepatic fat mobilization — that neither GLP-1 nor GIP agonism produces alone. The clinical consequence is the largest weight loss seen in a Phase 2 obesity trial to date, along with a distinct side-effect and safety profile (modestly elevated heart rate, potential for glycemic excursions) that tirzepatide does not share.
Myth
Because retatrutide produces more weight loss than tirzepatide, it must be better for everyone.
Reality
Weight-loss magnitude is one of several clinically relevant outcomes. Retatrutide's higher efficacy at 12 mg is accompanied by a glucagon-driven heart-rate effect and different tolerability trade-offs that may not suit every patient. Until head-to-head trials are completed and long-term safety data mature, relative ranking for individual patients cannot be determined. For many patients, tirzepatide or semaglutide will remain the optimal choice even after retatrutide is approved.
Myth
Retatrutide will cure obesity — you'll take it for 6–12 months and be done.
Reality
Obesity is a chronic, relapsing condition driven by neuroendocrine biology that reverts when pharmacological signal is removed. Every GLP-1-class drug studied with a discontinuation arm shows substantial weight regain within a year of stopping. Retatrutide is highly likely to behave the same way — no published evidence suggests it produces durable physiologic remodeling that persists after withdrawal. Framing it as a short-term cure misrepresents both the pharmacology and the condition.
Published Research
30 studiesComparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials
Retatrutide in type 2 diabetes mellitus and obesity: an overview
Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials
The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities
Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis
Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials
Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids
Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis
Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials
Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis
Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis
Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis
Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis
The power of three: Retatrutide's role in modern obesity and diabetes therapy
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice
Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Phase 2a trial demonstrating that retatrutide achieved over 80% relative reduction in liver fat at 48 weeks, with complete MASH resolution in a substantial proportion of patients — positioning it as a potential breakthrough treatment for metabolic liver disease.
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
Retatrutide showing promise in obesity (and type 2 diabetes)
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Phase 2 trial in 281 adults with type 2 diabetes showing retatrutide reduced HbA1c by up to 2.02% and body weight by up to 16.9% at 36 weeks, outperforming the active comparator dulaglutide on both endpoints.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Landmark Phase 2 NEJM trial (n=338) showing retatrutide achieved up to 24.2% body weight loss at 48 weeks with the 12mg dose — the highest weight loss ever recorded for an obesity drug at that time, establishing retatrutide as the leading candidate in next-generation obesity therapy.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
First-in-patient Phase 1b trial (n=72) establishing proof of concept for triple agonism, showing dose-dependent reductions in HbA1c (up to 1.56%) and body weight (up to 8.96 kg) over 12 weeks with an acceptable safety profile.
Popular Stacks Including Retatrutide
Quick Facts
- Class
- Triple GIP/GLP-1/Glucagon Receptor Agonist
- Tier
- A
- Evidence
- Emerging
- Safety
- Moderate Data
- Updated
- Apr 2026
- Citations
- 30PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.